Sylvain Barreau1,2, Alexa S Green1, Charles Dussiau1,2, Anne-Sophie Alary1,2, Anna Raimbault1,2, Stephanie Mathis1,2, Lise Willems3, Didier Bouscary2,3, Olivier Kosmider1,2, Valerie Bardet4,5, Michaela Fontenay1,2, Nicolas Chapuis1,2. 1. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Biologique, Paris, France. 2. Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, Paris, France. 3. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Centre, Service d'Hématologie Clinique, Paris, France. 4. Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Ile de France Ouest, Service d'Hématologie-Immunologie-Transfusion, Boulogne, France. 5. INSERM U1173, Université Versailles Saint Quentin en Yvelines, France.
Abstract
BACKGROUND: Multiparametric flow cytometry (MFC) was recently reported to be a helpful additional tool in the diagnosis of myelodysplastic syndromes (MDS). However, numerous aberrancies have been reported that makes their evaluation difficult as part of a routine diagnosis. METHODS: Here, we validated a 1-tube panel for the evaluation of granulocytic and monocytic maturation by MFC and correlated our findings with diagnosis and prognosis of MDS. A total of 251 samples with MDS suspicion were prospectively analyzed and compared to an internal reference database leading to the calculation of the Diff score. RESULTS: The associated specificity and sensitivity values of this scoring system were 92.1% and 60.4% in a first learning cohort and 96.7% and 65.2% in a second independent validation cohort. The combination of the Diff score with the concomitantly calculated Ogata score increased the sensitivity to 74.2% and 78.3% in the learning and validation cohorts, respectively. Finally, a normal Diff score in MDS patients was associated with a significant prolonged progression-free survival. CONCLUSIONS: Taken together, the present data indicate that our strategy is a sensitive and specific MFC tool for the diagnosis of MDS-related cytopenia(s) which could be also useful for predicting evolution of these diseases.
BACKGROUND: Multiparametric flow cytometry (MFC) was recently reported to be a helpful additional tool in the diagnosis of myelodysplastic syndromes (MDS). However, numerous aberrancies have been reported that makes their evaluation difficult as part of a routine diagnosis. METHODS: Here, we validated a 1-tube panel for the evaluation of granulocytic and monocytic maturation by MFC and correlated our findings with diagnosis and prognosis of MDS. A total of 251 samples with MDS suspicion were prospectively analyzed and compared to an internal reference database leading to the calculation of the Diff score. RESULTS: The associated specificity and sensitivity values of this scoring system were 92.1% and 60.4% in a first learning cohort and 96.7% and 65.2% in a second independent validation cohort. The combination of the Diff score with the concomitantly calculated Ogata score increased the sensitivity to 74.2% and 78.3% in the learning and validation cohorts, respectively. Finally, a normal Diff score in MDSpatients was associated with a significant prolonged progression-free survival. CONCLUSIONS: Taken together, the present data indicate that our strategy is a sensitive and specific MFC tool for the diagnosis of MDS-related cytopenia(s) which could be also useful for predicting evolution of these diseases.
Authors: Kyra van der Pan; Sandra de Bruin-Versteeg; Daniela Damasceno; Alejandro Hernández-Delgado; Alita J van der Sluijs-Gelling; Wouter B L van den Bossche; Inge F de Laat; Paula Díez; Brigitta A E Naber; Annieck M Diks; Magdalena A Berkowska; Bas de Mooij; Rick J Groenland; Fenna J de Bie; Indu Khatri; Sara Kassem; Anniek L de Jager; Alesha Louis; Julia Almeida; Jacqueline A M van Gaans-van den Brink; Alex-Mikael Barkoff; Qiushui He; Gerben Ferwerda; Pauline Versteegen; Guy A M Berbers; Alberto Orfao; Jacques J M van Dongen; Cristina Teodosio Journal: Front Immunol Date: 2022-09-14 Impact factor: 8.786